FDA Rx-To-OTC Switch Division Director Leonard-Segal Resigns
This article was originally published in The Tan Sheet
Executive Summary
Andrea Leonard-Segal’s leadership in FDA’s OTC program helped shift the agency toward considering an expanded switch paradigm, and her successor will enter a challenging regulatory environment, stakeholders say.